SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of cellular therapies in China, has received official approval under the 2025 Shenzhen Key Industry R&D Program.
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/Tesla%20dealership%20with%20cars%20in%20lot%20by%20Jetcityimage%20via%20iStock.jpg)
/Close%20up%20metal%20sockets%20on%20computer%20video%20board%20by%20YouraPechkin%20via%20Adobe%20Stock.jpeg)